Latest data from Symphony Health Solutions shows a decrease in Zubsolv tablets market share (4-week rolling average) by 0.05 percentage points to 5.49%. Compared with last week’s numbers the market share were up by 0.05 percentage points to 5.46%. TRx market share were also lower by 0.05 percentage points reaching 5.55% (4-week rolling average). From last week the market share were down 0.09 percentage points to 5.50%. The overall market (buprenorphine/naloxone products) grew by 6.9% (4-week rolling average) compared to last year. TRx shows a 4-week rolling average growth rate of 8.0% compared to last year.